Retatrutide 10mg — Triple GLP-1/GIP/Glucagon Agonist

Protocol

Reconstitution & Usage Protocol

Before applying: let the loaded dose lose its chill (only the amount to be injected) — hold the syringe in your hand for 2–3 minutes.

1Reconstitution

Materials: 1 vial of Retatrutide 10 mg · 1 vial of bacteriostatic water (BAC water) · U-100 insulin syringe (100 IU / 1 mL) · alcohol wipes.

Bring the vial to room temperature by taking it out of the fridge 15–20 minutes beforehand.
Disinfect the rubber stopper of both vials (peptide and BAC water) with an alcohol wipe. Let it dry for 30 seconds.
Draw 2 mL of bacteriostatic water into a syringe (equivalent to 200 IU on an insulin syringe, or use a 3 mL syringe).
Inject the water slowly into the Retatrutide vial, directing the stream against the inner wall of the vial — never directly onto the powder.
Do not shake. Swirl gently between the palms or let it rest for 3–5 minutes until the solution is clear.

Label the vial with the reconstitution date and store in the fridge (2–8 °C). Stable for 28–60 days.

2Concentration & Dosing

Reconstituting 10 mg in 2 mL → 5 mg/mL = 50 mcg per IU.

Target dose	Units	Volume
1 mg (initial)	20 IU	0.20 mL
2 mg (titration)	40 IU	0.40 mL
4 mg (standard)	80 IU	0.80 mL
8 mg (advanced)	160 IU	Split into 2 doses

Universal formula: IU = (dose in mg ÷ 5) × 100

3Application

Route

Subcutaneous in the abdomen (5 cm from the navel), front thigh or back of the arm.

Frequency

Once per week, on the same day.

Cycle

Standard cycle: 16–24 weeks with monthly evaluation. Rotate the injection site.

Recommended titration: start with 1 mg for the first 4 weeks → increase to 2 mg in weeks 5–8 → 4 mg from week 9 onward → 8 mg in advanced users according to tolerance.
Important: dose increases must always be made in consultation with your advisor, evaluating gastrointestinal tolerance, blood glucose and weight.
Before applying: let the loaded dose lose its chill (only the amount to be injected) — hold the syringe in your hand for 2–3 minutes.
After applying: gently massage the area for about 40 seconds to disperse the peptide and improve absorption.

Antes de aplicar: deje que la dosis cargada pierda el frío (solo la cantidad a inyectar) — sostenga la jeringa en la mano 2–3 minutos.

1Reconstitución

Materiales: 1 vial de Retatrutide 10 mg · 1 vial de agua bacteriostática (BAC water) · jeringa de insulina U-100 (100 UI / 1 mL) · toallitas de alcohol.

Atemperar el vial sacándolo de la nevera 15–20 minutos antes.
Desinfectar la tapa de goma de ambos viales (péptido y agua BAC) con toallita de alcohol. Dejar secar 30 segundos.
Cargar 2 mL de agua bacteriostática en una jeringa (equivale a 200 UI en jeringa de insulina, o bien usar una jeringa de 3 mL).
Inyectar el agua lentamente dentro del vial de Retatrutide, dirigiendo el chorro hacia la pared interior del vial — nunca directamente sobre el polvo.
No agitar. Girar suavemente entre las palmas o dejar reposar 3–5 minutos hasta que la solución quede transparente.

Etiquetar el vial con la fecha de reconstitución y guardar en nevera (2–8 °C). Estable por 28–60 días.

2Concentración y dosis

Reconstituyendo 10 mg en 2 mL → 5 mg/mL = 50 mcg por UI.

Dosis objetivo	Unidades	Volumen
1 mg (inicial)	20 UI	0,20 mL
2 mg (titulación)	40 UI	0,40 mL
4 mg (estándar)	80 UI	0,80 mL
8 mg (avanzada)	160 UI	Dividir en 2 dosis

Fórmula universal: UI = (dosis en mg ÷ 5) × 100

3Aplicación

Vía

Subcutánea en abdomen (a 5 cm del ombligo), muslo frontal o parte trasera del brazo.

Frecuencia

1 vez por semana, el mismo día.

Ciclo

Ciclo estándar: 16–24 semanas con evaluación mensual. Rotar sitio de inyección.

Titulación recomendada: iniciar con 1 mg las primeras 4 semanas → subir a 2 mg semanas 5–8 → 4 mg semanas 9+ → 8 mg en usuarios avanzados según tolerancia.
Importante: los aumentos de dosis deben hacerse siempre bajo consulta con su asesor, evaluando tolerancia gastrointestinal, glucemia y peso.
Antes de aplicar: dejar que la dosis cargada pierda el frío (solo la cantidad a inyectar) — sostener la jeringa en la mano 2–3 minutos.
Después de aplicar: masaje suave en la zona durante ~40 segundos para dispersar el péptido y mejorar absorción.

Avant l'application : laissez la dose prélevée perdre son froid (seulement la quantité à injecter) — tenez la seringue dans la main pendant 2 à 3 minutes.

1Reconstitution

Matériel : 1 flacon de Retatrutide 10 mg · 1 flacon d'eau bactériostatique (BAC water) · seringue à insuline U-100 (100 UI / 1 mL) · lingettes alcoolisées.

Tempérer le flacon en le sortant du réfrigérateur 15 à 20 minutes à l'avance.
Désinfecter le bouchon en caoutchouc des deux flacons (peptide et eau BAC) avec une lingette alcoolisée. Laisser sécher 30 secondes.
Prélever 2 mL d'eau bactériostatique dans une seringue (équivaut à 200 UI sur une seringue à insuline, ou utiliser une seringue de 3 mL).
Injecter l'eau lentement dans le flacon de Retatrutide, en dirigeant le jet vers la paroi intérieure du flacon — jamais directement sur la poudre.
Ne pas secouer. Faire tourner doucement entre les paumes ou laisser reposer 3 à 5 minutes jusqu'à ce que la solution soit transparente.

Étiqueter le flacon avec la date de reconstitution et conserver au réfrigérateur (2–8 °C). Stable pendant 28 à 60 jours.

2Concentration et dosage

En reconstituant 10 mg dans 2 mL → 5 mg/mL = 50 mcg par UI.

Dose cible	Unités	Volume
1 mg (initial)	20 UI	0,20 mL
2 mg (titration)	40 UI	0,40 mL
4 mg (standard)	80 UI	0,80 mL
8 mg (avancée)	160 UI	Diviser en 2 doses

Formule universelle : UI = (dose en mg ÷ 5) × 100

3Application

Voie

Sous-cutanée dans l'abdomen (à 5 cm du nombril), face avant de la cuisse ou arrière du bras.

Fréquence

1 fois par semaine, le même jour.

Cycle

Cycle standard : 16 à 24 semaines avec évaluation mensuelle. Alterner le site d'injection.

Titration recommandée : commencer par 1 mg les 4 premières semaines → passer à 2 mg semaines 5–8 → 4 mg à partir de la semaine 9 → 8 mg chez les utilisateurs avancés selon la tolérance.
Important : les augmentations de dose doivent toujours se faire en consultation avec votre conseiller, en évaluant la tolérance gastro-intestinale, la glycémie et le poids.
Avant l'application : laisser la dose prélevée perdre son froid (seulement la quantité à injecter) — tenir la seringue dans la main pendant 2 à 3 minutes.
Après l'application : masser doucement la zone pendant environ 40 secondes pour disperser le peptide et améliorer l'absorption.

Open dosage calculator →

Research Highlights

Obesity clinical-trial data reported average body-weight reductions exceeding 24% over 48 weeks, the greatest documented for a single agent in its class.
Study models attribute the glucagon arm to increased basal energy expenditure and hepatic fat oxidation, complementing the appetite suppression driven by GLP-1.
Parallel GLP-1, GIP and glucagon activation is reported to improve insulin sensitivity and the glycemic, lipid and hepatic profile in research settings.

FAQ

Frequently Asked Questions

What is Retatrutide and what makes it a triple agonist?

Retatrutide (LY3437943) is a research peptide developed by Eli Lilly that activates three metabolic receptors in parallel: GLP-1 (appetite suppression), GIP (insulin sensitivity) and glucagon (basal energy expenditure). This triple-receptor profile distinguishes it from the dual and single agonists studied in metabolic research, and reported study data describe average weight reductions above 24% of body weight over 48 weeks. It is supplied strictly for in-vitro and laboratory use.

How is the 10 mg vial reconstituted and what concentration does it yield?

In the laboratory reference, 10 mg is reconstituted in 2 mL of bacteriostatic water, yielding 5 mg/mL, which equals 50 mcg per IU on a U-100 insulin syringe. On this basis a 1 mg quantity corresponds to 20 IU (0.20 mL) and a 4 mg quantity to 80 IU (0.80 mL). The universal formula is IU = (dose in mg ÷ 5) × 100. These figures describe volumetric measurement for research only.

How does Retatrutide differ from dual GLP-1/GIP agonists in research models?

Dual agonists activate only GLP-1 and GIP, whereas Retatrutide adds a third arm: glucagon-receptor activation, which in study data is associated with increased basal energy expenditure, hepatic fat oxidation and greater observed fat loss. This glucagon component is what distinguishes it from the rest of the GLP-1 analogs and underlies its reported synergistic metabolic effect. Both classes are research-only compounds and are not interchangeable in study design.

What administration route and schedule appear in the research reference?

The reference describes subcutaneous administration in the abdomen (5 cm from the navel), front thigh or back of the arm, once per week on the same day. The titration scheme starts at 1 mg for the first 4 weeks, rises to 2 mg in weeks 5–8, then 4 mg from week 9, and 8 mg for advanced users according to tolerance, within a standard 16–24 week cycle with monthly evaluation and site rotation. These figures describe the literature only and are not human-use instructions.

Related Compounds

← Back to full catalog